Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
ABOS | US
Overview
Corporate Details
- ISIN(s):
- US00509G2093
- LEI:
- Country:
- United States of America
- Address:
- 1210-1220 WASHINGTON STREET, 2465 NEWTON
- Website:
- https://acumenpharm.com/
- Sector:
- Manufacturing
Description
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease. The company's approach is based on research into toxic soluble amyloid beta oligomers (AβOs), which are considered a primary driver of neurodegeneration associated with the disease. Its lead product candidate, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target these toxic AβOs. Sabirnetug is being developed as a potential disease-modifying treatment for early Alzheimer's, with the goal of providing therapeutic benefits with an improved safety profile.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Acumen Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Acumen Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Acumen Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
